Abstract:Purpose: This study evaluates MALT1 as a potential therapeutic target in H3K27-altered diffuse midline glioma (DMG). Background: H3K27-altered DMG is a devastating pediatric brain tumor that affects 200-300 individuals in the US per year. Median survival is 9-11 months, and there are virtually no long-term survivors. Despite decades of clinical trials, radiation therapy remains standard of care, extending survival by 2-3 months. Development of effective therapies for H3K27-altered DMG is a critical unmet need. MALT1 is the effector molecule of the CARMA-BCL10-MALT1 (CBM) signalosome, a cytoplasmic protein complex that drives downstream signaling, including activation of the pro-survival NF-kB transcription factor. MALT1, which possesses distinct scaffolding and protease activities, has been best characterized as an oncogenic driver in multiple lymphomas. More recently, MALT1 has been shown to act in multiple solid tumor types (breast, lung, glioblastoma) to promote cell viability, proliferation, and migration/invasion. Based on these studies, we hypothesize that MALT1 promotes H3K27-altered DMG cancer cell proliferation and survival and that MALT1 inhibition will abrogate DMG tumor progression. Methods/Results: We screened a panel of patient-derived DMG cell lines by Western blot and found that the CBM signalosome components BCL10 and MALT1 are present in all cell lines tested. We next optimized a brain-penetrant lipid nanoparticle (LNP) delivery system to achieve efficient siRNA knockdown in non-adherent DMG cells and utilized this approach to knockdown MALT1 in DIPG07, BT245, and DIPG XIII FL cell lines. Preliminary findings indicate that loss of MALT1 leads to a reduction in DMG cell viability. To complement this RNAi-based approach, we utilized the blood brain barrier (BBB)-penetrant small molecule MALT1 inhibitor "M1i-124." This compound, discovered in our laboratory, is a protein-protein interaction inhibitor that disrupts the binding of BCL10 and MALT1 and blocks both MALT1 scaffold and protease activities (manuscript in revision). M1i-124 treatment, at nanomolar-range doses, reduces the viability of both DIPG07 and BT245 DMG cell lines. Conclusions: We found that both siRNA-mediated MALT1 knockdown and the small molecule MALT1 inhibitor M1i-124 are toxic to DMG cells. These preliminary findings point to the potential for therapeutic targeting of MALT1 in H3K27-altered DMG. Future Directions: We will next evaluate the mechanism by which MALT1 knockdown or pharmacological inhibition impacts DMG cell survival using RNA-sequencing and proteomics approaches. We will also use H3K27-altered DMG xenograft models to evaluate the impact of MALT1 inhibition on H3K27-altered DMG tumor progression in vivo. Citation Format: Hannah Butterfield, Juliana Hofstatter Azambuja, Lisa Maurer, Saigopalakrishna S. Yerneni, Andrea Cruz, Matthew Halbert, Taylor Gatesman, Sameer Agnihotri, Peter C. Lucas, Linda M. McAllister-Lucas. MALT1 as a regulator of tumor progression in H3K27-altered diffuse midline glioma [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1) nr A002.

Changes in mucosa‐associated lymphoid tissue 1 predicts therapeutic response and survival in patients with advanced melanoma receiving programmed cell death‐1 inhibitor monotherapy

Blood MALT1 Deficiency is Common and Relates to Unfavorable Induction Therapy Response and Survival Profile in Acute Myeloid Leukemia Patients.

Blood MALT1 expression could help predict treatment outcomes in psoriasis patients, especially in those receiving biologics

1262PSoluble PD-L1 as a prognostic factor in advanced acral and mucosal melanoma

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy

Lower Tumor Mutational Burden (TMB) and Hepatic Metastases May Predict for Lack of Response to PD-1 Blockade in MSI-H Metastatic Colorectal Cancer (MCRC).

Association of Peripheral Blood Biomarkers with Response to Anti-PD-1 Immunotherapy for Patients with Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.

Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients

Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy

Clinical Significance of MALT1 Gene Detection in Extra-nodal B Cell Lymphoma

Abstract A002: MALT1 as a regulator of tumor progression in H3K27-altered diffuse midline glioma

Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.

Survival analysis of comprehensive treatment in Chinese patients with metastatic melanoma: A retrospective analysis

Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study

Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer

Baseline Lesion Number As an Efficacy Predictive and Independent Prognostic Factor and Its Joint Utility with TMB for PD-1 Inhibitor Treatment in Advanced Gastric Cancer

The Association Between Monocytic Myeloid-Derived Suppressor Cells Levels and the Anti-Tumor Efficacy of Anti-Pd-1 Therapy in NSCLC Patients

Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma

Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment